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Background: Approximately 50% of patients with the clinical features of chronic heart failure (HF) experience HF with preserved ejection fraction 
(HFPEF). There are as yet no specific, proven, life saving therapies for this form of HF. In these patients, diastolic dysfunction caused by hypertensive 
heart disease (HHD) is implicated as a major contributor. NO based therapies may have anti-remodelling benefits. An accumulation of fibrous tissue, 
or fibrosis, is an established morphological feature of HHD and HFPEF. Matrix metalloproteinases (MMPs) play an important role in inflammation and 
fibrosis. Novel dual anti-remodelling therapies may be of benefit in HHD and HFPEF.
Methods: A range of NO-releasing MMP inhibitors were generated using standard synthetic approaches from existing MMP-inhibitory scaffolds. 
Effects on MMP2/9 production were assessed by incubating the compounds in the range 0.10-100μM in the presence of HT1080 cells that were 
stimulated with PMA. After 24 h, the supernatants were sampled and assessed by zymography on gelatine-based gels. Effects on cell viability were 
assessed by MTT assay. Nitrite/nitrate was assessed by Greiss method. Intrinsic inhibitory potency was measured using recombinant MMPs with 
fluorescent substrates.
Results: The novel NO-modified compounds inhibited the expression of MMP2/9 as evidenced by gelasinase zymography/densitomitry. 
ST071002 and ST1003 exhibited intrinsic MMP affinity (IC50s 50-120nM) specific for MMP2 and MMP9 and in cell suspensions they produced 
pharmacologically relevant levels of nitric oxide. These compounds are the first prototypes of a new pharmaceutical strategy for HFPEF involving 
inhibition at two levels of enzymes involved in remodelling and production of NO.
Conclusions:  These novel, nitric oxide releasing MMP inhibitors may be effective dual anti-remodelling therapies in HFPEF.
